R Wong1, D Cunningham2, Y Barbachano3, C Saffery1, J Valle4, T Hickish5, S Mudan6, G Brown7, A Khan6, A Wotherspoon8, A S Strimpakos1, J Thomas1, S Compton1, Y J Chua1, I Chau1. 1. Department of Medicine. 2. Department of Medicine. Electronic address: david.cunningham@rmh.nhs.uk. 3. Department of Clinical Research and Development, Royal Marsden Hospital NHS Foundation Trust, Sutton. 4. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester. 5. Department of Haematology and Oncology, Royal Bournemouth and Poole Hospital, Dorset. 6. Department of Academic Surgery. 7. Department of Diagnostic Imaging. 8. Department of Histopathology, Royal Marsden Hospital NHS Foundation Trust, London, UK.
Abstract
BACKGROUND: Perioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection. PATIENTS AND METHODS: Poor-risk CLM was defined as follows: more than four metastases, diameter >5 cm, R0 resection unlikely, inadequate viable liver function if undergoing upfront resection, inability to retain liver vascular supply, or synchronous colorectal primary presentation. Patients underwent baseline computed tomography, magnetic resonance imaging, and/or positron emission tomography (PET) for staging and received neoadjuvant CAPOX plus bevacizumab, with resectability assessed every four cycles. Primary end point was radiological objective response rate (ORR). RESULTS: Forty-six patients were recruited, of which 91% underwent PET to ensure metastases confined to liver. Following neoadjuvant CAPOX plus bevacizumab, the ORR was 78% (95% confidence interval 63% to 89%). This allowed 12 of 30 (40%) patients with initial nonsynchronous unresectable CLM to be converted to resectability. In addition, 10 of 15 (67%) patients with synchronous resectable CLM underwent liver resection, with four additional patients being observed alone due to excellent response to neoadjuvant therapy. No grade 3-4 perioperative complications were seen. CONCLUSION: Neoadjuvant CAPOX plus bevacizumab resulted in a high response rate for patients with CLMs with poor-risk features not selected for upfront resection and converted 40% of patients to resectability.
BACKGROUND: Perioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection. PATIENTS AND METHODS: Poor-risk CLM was defined as follows: more than four metastases, diameter >5 cm, R0 resection unlikely, inadequate viable liver function if undergoing upfront resection, inability to retain liver vascular supply, or synchronous colorectal primary presentation. Patients underwent baseline computed tomography, magnetic resonance imaging, and/or positron emission tomography (PET) for staging and received neoadjuvant CAPOX plus bevacizumab, with resectability assessed every four cycles. Primary end point was radiological objective response rate (ORR). RESULTS: Forty-six patients were recruited, of which 91% underwent PET to ensure metastases confined to liver. Following neoadjuvant CAPOX plus bevacizumab, the ORR was 78% (95% confidence interval 63% to 89%). This allowed 12 of 30 (40%) patients with initial nonsynchronous unresectable CLM to be converted to resectability. In addition, 10 of 15 (67%) patients with synchronous resectable CLM underwent liver resection, with four additional patients being observed alone due to excellent response to neoadjuvant therapy. No grade 3-4 perioperative complications were seen. CONCLUSION: Neoadjuvant CAPOX plus bevacizumab resulted in a high response rate for patients with CLMs with poor-risk features not selected for upfront resection and converted 40% of patients to resectability.
Authors: Gonzalo Recondo; Enrique Díaz-Cantón; Máximo de la Vega; Martin Greco; Gonzalo Recondo; Matias E Valsecchi Journal: World J Gastrointest Oncol Date: 2014-07-15
Authors: Andreas Andreou; Thomas A Aloia; Antoine Brouquet; Paxton V Dickson; Giuseppe Zimmitti; Dipen M Maru; Scott Kopetz; Evelyne M Loyer; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2013-06 Impact factor: 12.969
Authors: Kathleen De Greef; Christian Rolfo; Antonio Russo; Thiery Chapelle; Giuseppe Bronte; Francesco Passiglia; Andreia Coelho; Konstantinos Papadimitriou; Marc Peeters Journal: World J Gastroenterol Date: 2016-08-28 Impact factor: 5.742